Prof Hervé Le Louët is the new CEO of WHO Uppsala International Drug Monitoring Center,
Past President of CIOMS - Council of International Organizations of Medical Sciences established by WHO World Health Organization designing guidelines and standards, basis of all the regulations worldwide.
Prof Hervé has supported the creation of the Israeli Chapter when he was President of ISOP. He is a Member of the ISOP ISRAEL Advisory Board from its creation.

 

Hervé Le Louët is a Professor of Clinical Pharmacology. He is currently the head of the Pharmacovigilance department of Paris University-Hospitals (AP-HP). He is a hepatologist by training and has a Ph.D. in Pharmacogenetic from the East Paris University.

​

He is the President of the Council for International Organizations for Medical Sciences (CIOMS) and immediate Past President of the International Society of Pharmacovigilance (ISoP).

​

He was co-opted member by the European Commission of the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency.

​

He is a member of the board of the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) and is an Honorary Consultant for Uppsala Monitoring Centre (WHO). He was the advisor of the Minister of Health and Social Security.

 

He worked on liver metabolism assessment in patients with different liver conditions and on the drug-induced mitochondria toxicity. He also worked on serious cutaneous adverse reactions (SCAR), especially on causality assessment for Steven Johnson Syndrom and Toxic Epidermal Necrolysis. He has learning activities in several universities worldwide.